Outcome of Board Meeting

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 3rd November 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Outcome of the Board Meeting We wish to inform you that a meeting of the Board of Directors of the Company was held today, i.e. 3rd November 2026 and inter alia, transacted the following business: 1. Financial Results Pursuant to Regulation 33 read with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, enclosed herewith are the Un-audited Standalone and Consolidated Financial Results for the second quarter & half year ended 30th September 2026, approved by the Board of Directors of the Company at it is meeting held today along with the Limited Review Report of the Auditors. 2. Change in Senior Management In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that Mr. Sandeep Seth has been appointed as Head - Ethics & Compliance effective today. 3. Change in Statutory Auditors Upon the recommendation of the Audit Committee, the Board of Directors, at its meeting held on 3 November 2026, approved the appointment of M/s Walker Chandiok & Co LLP, Chartered Accountants (Firm Registration No. 001076N/N500013), as the Statutory Auditors of the Company for a first term of five consecutive years, commencing from the financial year 2027-28 and continuing until the conclusion of the 107th Annual General Meeting of the Company to be held in respect of the financial year 2031-32, subject to the approval of the Members at the ensuing Annual General Meeting of the Company. The additional details required under the SEBI Listing Regulations read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and Exchange Circular List/Comp/14/2018-19 dated June 20, 2018, are enclosed as Annexure A & B respectively. The Meeting of the Board of Directors of the Company commenced at 3.45 p.m. and concluded at 6.00 p.m. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary Encl: a. a CIN: L24239MH1924PLC001151 Annexure A Sr no Particulars Details 1 Reason Appointment 2 Date of Appointment/ Cessation Mr. Sandeep Seth has been appointed as and Term Head - Ethics & Compliance, today i.e. 3rd November 2026 3 Disclosure of relationship with None Directors 4 Brief Profile Sandeep brings more than 20 years of experience in ethics, compliance and governance across the pharmaceutical, consumer healthcare and health insurance sectors. He has led compliance programmes fostered ethical culture and partnered with business leaders to enable responsible growth and effective decision- making. Prior to joining GSK, Sandeep served as Head of Ethics & Business Integrity for Opella, supporting markets across India, Africa, the Middle East and Turkey. He has also held compliance leadership roles with Pfizer, MSD Pharma and Max Bupa Health. Sandeep is a qualified lawyer, a member of the Institute of Company Secretaries of India, a Certified Compliance Professional and Certified Fraud Examiner, and holds degrees in Commerce and Law from Delhi University. In his new role, Sandeep will be part of the APAC Compliance leadership team and the India Leadership Team. Annexure B Appointment of M/s. Walker Chandiok as the Statutory Auditors of the Company Sr no Particulars Details 1 Reason Appointment 2 Date of Appointment/ Cessation Appointment M/s Walker Chandiok & Co and Term LLP, Chartered Accountants (Firm Registration No. 001076N/N 500013) as the Statutory Auditors of the Company for a first term of 5 (five) years i.e. , from financial year 2027-28 to the financial year 2031-32 i.e , to hold office till the conclusion the 107th Annual General Meeting of the Company subject to approval of the Members at the forthcoming Annual General Meeting of the Company. 3 Disclosure of relationship with None Directors 4 Brief Profile M/s. Walker Chandiok & Co LLP (Firm Registration no. 001076N/N500013) is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India (ICAI), Public Company Accounting Oversight Board (PCAOB) and empaneled with Comptroller and Auditor General of India (CAG). The firm was established in the year 1935 and its registered office is situated at New Delhi with Nineteen other offices across major cities in India. It has ninety- nine partners. It has a valid peer review certificate and is one of India’s leading audit firms providing audit and assurance services to several large companies including some of the top one hundred listed entities in India. GlaxoSmlthKllne Phannaceutlcals Limited Realstered Office: Dr. Annie Besant Road Mumbai -400 030 CIN: L24239MH19Z4PLC001151 Tel Na: +91 22 2495 9595 Fax No: +91 22 24959494 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE OUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2026 (Rs. In Lakhs) Preceding Corresponding Particulars 3 months ended 3 months ended 3 months ended 6 months ended 6 months ended Year ended 30.09.2026 30.06,2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited} (Unaudited} (Unaudited) (Audited) Income 1 Revenue from operatlons 117991 92442 97363 210433 177846 379020 2 Other Income (Refer Note 2) 7277 6163 3127 13440 7503 14256 3 Total Income (1+2) 125268 98605 100490 223873 185349 393276 Expenses (a) Cost of materials consumed 11690 5987 10707 17677 22850 40007 (b) Purchases of stock-In-trade 27904 37862 23271 65766 46478 91044 (c) Changes In Inventories of finished goods, stock-In- trade and work-In-progress 4176 (12204) 1076 (8028) (5477) 1350 (d) Employee benefits expense 17019 15904 13805 32923 29062 60725 (e) Finance costs 49 97 51 146 93 273 (f) Depreclatlon and amortisation expense 1502 1584 1743 3086 3295 6644 (g) Other expenses 17170 15577 15036 32747 26390 55874 4 Total expenses 79510 64807 65689 144317 122691 255917 5 Profit before exception al Items and tax (3-4} 45758 33798 34801 79556 62658 137359 6 Exceptional Items (c redit) (Refer Note 3) C 264 264 264 7 Pr~flt before tax (5+6} 4!1758 33798 35065 79556 62922 137623 8 Tax expense (a) Current tax 12127 8135 9521 20262 16906 35495 ( b) Deferred tax 169 330 44 499 46 946 9 Profit for the aerlod/vear l7•8l ._ 33462 25333 25500 58795 45970 101182 GlaxoSmlthKllne Pharmaceuticals Limited Realstered Office: Dr. Annie Besant Road Mumbai • 400 030 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE OUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER. 2026 (Rs. In Lakhs' Preceding Corresponding Particulars 3 months ended 3 months ended 3 months ended 6 months ended 6 months ended Year ended 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31,03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 10 Other comprehensive Income/ (loss) . . . . . (I) Items that will not be reclasslfled to profit or loss (99B) (II) Income tax relating to Items that will not be . . . . . reclasslned to profit or loss 244 11 Total comprehensive Income for the period (9+10) 33462 25333 25500 58795 45970 100428 Paid-up equity share capital (face value per share Rs. 10) 16941 16941 16941 16941 16941 16941 Other equity 207177 Earnings per share (EPS) (of Rs. 10 each) Basic and dlluted EPS before Exceptional Items (Rs.) 19.76 14.95 14.92 34.71 27.00 59.59 Basic and diluted EPS a~er Exceptional Items (Rs.) 19.76 14.95 15.06 34.71 27.14 59.73 Not Annualised Statement of Assets and Liabilities Standalone Rs. [Showing first 8,000 characters — download PDF for full document]